Press release
New Analysis Finds Sotagliflozin to Be a Cost-Effective Treatment at Commonly Accepted Willingness-to-Pay Threshold in Patients with Worsening Heart Failure
Sotagliflozin reduced the risk of cardiovascular death and heart failure readmissions in patients hospitalized for worsening heart failure events in
About this update from Lexicon Pharmaceuticals, Inc.
[{"type":"text","content":"Sotagliflozin reduced the risk of cardiovascular death and heart failure readmissions in patients hospitalized for worsening heart failure events in SOLOIST-WHF study Sotagliflozin NDA for treatment of heart failure on track for May 27, 2023 PDUFA action date THE WOODLANDS, Texas, May 10, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that results of a new investigator-initiated economic analysis, based on results from the SOLOIST-WHF Phase 3 outcomes study of its investigational medicine sotagliflozin, were presented on May 9 at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting in Boston, Massachusetts. The analysis was led by the MedStar Health Research Institute in Washington, D.C. and was conducted from a U.S. healthcare sector perspective, in accordance with Consolidated Health Economic Evaluation Reporting Standards. The analysis was based on nine-month median follow-up data from the 1,222 patients enrolled in the Phase 3 SOLOIST-WHF trial and designed to extrapolate costs, life expectancy, and quality-adjusted life expectancy to estimate sotagliflozin’s cost-effectiveness. The researchers determined that sotagliflozin is a clinically and economically attractive medication and is cost-effective at commonly accepted willingness-to-pay thresholds in patients with diabetes and worsening heart failure. Heart failure is the leading cause of hospitalization for Americans over the age of 65. Patients with heart failure are at highest risk of having a repeat heart failure event in the first 30 days post-discharge, with 7% dying and 25% being rehospitalized within one month. “With the prevalence of heart failure rising at an ever-increasing rate and hospitalizations driving a significant majority of healthcare costs relating to heart failure, it is clear that we need to do more,” said Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer. “We are closer than ever to potentially providing an additional treatment option for heart failure patients transitioning out of the hospital and helping to reduce the financial and physical burdens of rehospitalizations.” Results from SOLOIST-WHF showed that sotagliflozin significantly reduced hospitalizations for heart failure, urgent visits for heart failure, and the risk of card...